Not only has the fund performed well, but it has also seen some exciting data, according to YCharts. The fund's price has risen above both its 50 and 200-day simple moving averages (SMAs), historically an indicator of healthy momentum and a buy signal. In the shifting landscape of ETFs, many funds claim to offer exposure to innovation. Technology plays a key role as a growth industry and a driver for performance across the economy overall, as well. With potentially multiple rate cuts on the horizon, then, i ...

In trading on Wednesday, shares of Akero Therapeutics Inc (Symbol: AKRO) crossed below their 200 day moving average of $43.26, changing hands as low as $42.55 per share. Akero Therapeutics Inc shares are currently trading down about 3.1% on the day. The chart below shows the one year performance of AKRO shares, versus its 200 day moving average:Looking at the chart above, AKRO's low point in its 52 week range is $21.34 per share, with $58.40 as the 52 week high point — that compares with a last trade of $4 ...

PresentationMichael UlzEquity Analyst All right. Well, good morning, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference. I'm Mike Ulz, one of the biotech analysts here, and it's my pleasure to introduce Andrew Cheng, CEO for Akero Therapeutics. Before we get started, I just need to read a quick disclaimer. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. And if you have any questions, please ...

Akero Therapeutics (NasdaqGS:AKRO) FY Conference September 08, 2025 10:45 AM ET Company ParticipantsAndrew Cheng - President, CEO & DirectorMichael Ulz - Executive Director - Biotechnology Equity ResearchMichael UlzGood morning, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference. I'm Mike Goldsmith, a biotech analyst here, and it's my pleasure to introduce Andrew Cheng, CEO from Akero Therapeutics. Before we get started, I just need to read a quick disclaimer for importan ...

Company Overview - Akero Therapeutics, Inc. is a clinical-stage company focused on developing transformational treatments for serious metabolic diseases with high unmet medical needs, including metabolic dysfunction-associated steatohepatitis (MASH) [3] Upcoming Events - Management will present at the Morgan Stanley 23 Annual Global Healthcare Conference on September 8, 2025, at 10:45 a.m. E.T. in New York, NY [1] Product Development - Akero's lead product candidate, efruxifermin (EFX), is currently being evaluated in three ongoing Phase 3 clinical studies targeting different patient populations with MASH [3] - The Phase 3 SYNCHRONY program builds on results from two Phase 2b clinical trials: the HARMONY study for pre-cirrhotic MASH and the SYMMETRY study for compensated cirrhosis due to MASH [3]

Core Insights - The publication of the 96-week results from the Phase 2b HARMONY trial indicates the potential of efruxifermin (EFX) to significantly reduce the risk of fibrosis progression in patients with pre-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) [1][2][3] Company Overview - Akero Therapeutics, Inc. is a clinical-stage company focused on developing treatments for serious metabolic diseases, particularly MASH, which has a high unmet medical need [1][12] - Efruxifermin (EFX) is Akero's lead product candidate, currently being evaluated in three ongoing Phase 3 studies targeting different stages of MASH [9][12] Trial Results - The HARMONY trial was a 96-week multicenter, randomized, double-blind, placebo-controlled study involving 128 adult participants with biopsy-confirmed MASH and moderate to advanced fibrosis [2][11] - In the mITT population at week 96, 49% of participants receiving 50mg EFX achieved at least one stage of fibrosis improvement without worsening of MASH, compared to 19% for placebo (p=0.0030) [3][4] - Improvements in fibrosis were also noted in patients with more advanced disease, indicating EFX's potential effectiveness across different stages of MASH [3][4] Secondary Endpoints - The secondary endpoint of MASH resolution without fibrosis worsening was achieved by 40% of participants receiving 28mg EFX and 37% receiving 50mg EFX, compared to 19% for placebo [4] - A composite endpoint of both MASH resolution and at least one stage of fibrosis improvement was met by 35% and 28% of participants in the 50mg and 28mg EFX groups, respectively, versus 7% for placebo [4] Safety and Tolerability - EFX was generally well tolerated, with a safety profile consistent with previous trials; the most common adverse events were mild to moderate gastrointestinal issues [6] - A small reduction in bone mineral density was observed after 96 weeks of EFX treatment, although the clinical significance of this finding remains to be determined [6] Overall Impact - The sustained reductions in fibrosis and MASH observed in the trial reflect an overall improvement in whole-body metabolic health, including reduced dyslipidemia and increased insulin sensitivity [7] - The results from the HARMONY trial, along with data from the SYMMETRY trial, suggest that EFX has the potential to transform patient outcomes, particularly for those with a high fibrosis burden [3][7]

Aveanna Healthcare (AVAH) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 49.5%. For Aveanna Healthcare, the consensus EPS estimate for the current year has increased 87% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy). To break things down more, Akero Therapeutics, Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 489 individual companies and currently sit ...

Exhibit 99.1 Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Published results from the 96-Week Phase 2b SYMMETRY trial in the New England Journal of Medicine Three presentations at the EASL Congress 2025 highlighted data demonstrating statistically significant reversal of compensated cirrhosis (F4) due to MASH and corroborating the anti-fibrotic activity of EFX seen in patients with pre-cirrhotic (F2-F3) MASH Cash, cash equivalents and short and long-term marke ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 Delaware 81-5266573 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 601 Gateway Boulevard, Suite 350 South San Francisco, CA 94080 (650) 487-6488 (Address, including zip code, and telephone number, including area code, ...

Core Insights - Akero Therapeutics reported significant advancements in its clinical program for Efruxifermin (EFX), particularly in reversing compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH) as demonstrated in the Phase 2b SYMMETRY trial [1][2][7] Financial Performance - As of June 30, 2025, Akero had cash, cash equivalents, and short-term marketable securities totaling $1,086.2 million, which is expected to fund operations into 2028 [1][13] - Research and development expenses for Q2 2025 were $69.3 million, up from $55.3 million in Q2 2024, attributed to ongoing Phase 3 studies and increased personnel costs [13] - General and administrative expenses rose to $11.6 million in Q2 2025 from $10.4 million in Q2 2024, reflecting higher personnel and professional service costs [13] - Total operating expenses for Q2 2025 were $80.9 million, compared to $65.7 million in the same period of 2024 [13] Clinical Developments - The Phase 2b SYMMETRY trial results were published in the New England Journal of Medicine, reinforcing EFX's potential as a first- and best-in-class therapy for advanced-stage MASH [7] - EFX demonstrated the ability to reverse cirrhosis in high-need subgroups, including patients with cryptogenic cirrhosis and type 2 diabetes, marking a significant milestone in treatment options [7] - The Phase 2b HARMONY study also showed consistent improvements in fibrosis for patients with pre-cirrhotic MASH, utilizing both conventional and AI-based analysis methods [7] Market Context - MASH affects an estimated 17 million Americans, with approximately 20% of patients expected to progress to cirrhosis, highlighting the urgent need for effective treatments [8] - By 2030, it is projected that 3 million Americans will have cirrhosis due to MASH, emphasizing the growing public health challenge [9]